source
- Gilead’s emvistegrast shows superior response to placebo in Phase 2 ulcerative colitis trialGilead Sciences reported that its investigational oral drug emvistegrast achieved a higher clinical response rate than placebo in a Phase 2 study of ulcerative colitis. The trial enrolled 238 patie…
- FDA, MHRA officials eye streamlined frameworks for regulating genAIBoston – Regulators from the US and UK discussed ongoing efforts to develop regulatory frameworks that are better suited to generative artificial intelligence (genAI) products at The MedTech Confer…raps · 23h ago↗ source